Personal information

Verified email domains

Autoimmunity, Antibodies, Tumour associated antibodies, Immunology
Spain

Biography

Graduated in Medicine in 2002 and specializing in Immunology in 2008, with a Diploma in Advanced Studies in Immunology obtained in 2007 from the Autonomous University of Barcelona, JF Delgado has established a career serving as a senior physician specialist in Immunology at the Parc Taulí Hospital Universitari of Sabadell since June 2008, he also holds the position of associate professor at the Department of Cellular Biology, Physiology, and Immunology at the Universitat Autònoma of Barcelona since September 2014.

During his residency at the Immunology Service of the Hospital de la Santa Creu i Sant Pau, a renowned national center for autoimmunity, he dedicated his research efforts to various aspects of rheumatoid arthritis (RA). His investigations encompassed a wide range of topics, from exploring the presence of autoantibodies against the citrullinated shared epitope in RA patients, leading to a national congress presentation in 2005, to examining the influence of genetic polymorphisms, particularly the LILRB1 gene, on RA, resulting in national and international communications and a national publication. Subsequently, he delved into studying the presence of anti-cyclized citrullinated peptide antibodies, the more specific diagnostic criteria for RA, in patients with dermatomyositis, yielding an international publication and further communication.

As a consultant physician at the Parc Taulí Hospital Universitari, JF Delgado has received approval from the Clinical Research Ethics Committee of the hospital for various investigations over the past five years. These include: to develope a rapid diagnostic test for COVID-19 based on the detection of antibodies in 2020. Study of prognostic value of specific T lymphocyte populations against SARS-CoV-2 in long-term hospitalized infected patients in 2021. SARS-CoV-2 infection and the original antigenic sin hypothesis in 2022. Presence of anti-SARS-COV-2 antibodies of the IgE isotype in patients with severe COVID-19 in 2022. In addition, JF Delgado participates as research collaborator in these approved studies: Population study of the immune response against SARS-CoV-2, health professionals, patients with COVID-19 infection, contacts and the general population, from the reference area of the Parc Taulí University Hospital, Sabadell in 2020. Impact of sleep disorders on innate immunity in COVID-19 patients in 2022. Study of the immune response to the COVID-19 vaccine in patients with mental disorders under treatment with clozapine compared to populations without clozapine in 2022 and Detection of lost opportunities due to the diagnosis of HIV infection at the Parc Taulí University Hospital in 2023.

In the realm of innovation, JF Delgado has spearheaded a project aimed at detecting antibodies against tumor-associated antigens in hepatocellular carcinoma. This project has garnered recognition through various innovation competitions, including the "KIC-Cross Business Idea Competition" of EIT-Health, where it secured third place, and the IMPACTE program of CIMTI. These platforms offer mentoring programs to facilitate the transition of innovative ideas to market. Notably, the project has resulted in a patent application through the Patent Cooperation Treaty, receiving a favorable report (PCT/ EP2021/071238).

JF Delgado's research portfolio encompasses the characterization of autoantibodies in autoimmune diseases, studies on the immunogenetics of autoimmune diseases, investigations into autoantibodies against tumor-associated antigens in tumor pathology, and studies of antibody immune responses in SARS-CoV-2 infection and vaccination.

Activities

Employment (2)

Institute of Research and Innovation Parc Tauli: Sabadell, ES

Employment
Source: Self-asserted source
Juan Francisco Delgado

Parc Taulí Hospital Universitari: Sabadell, Catalunya, ES

2008-06-03 to present | Senior doctor (Laboratory. Immunology Section)
Employment
Source: Self-asserted source
Juan Francisco Delgado

Education and qualifications (2)

Hospital de la Santa Creu i Sant Pau: Barcelona, Catalunya, ES

2004 to 2008 | Especialista en Inmunología
Qualification
Source: Self-asserted source
Juan Francisco Delgado

Facultad de Medicina Universidad de Sevilla: Sevilla, Andalucía, ES

1996 to 2002 | Medicina
Education
Source: Self-asserted source
Juan Francisco Delgado

Professional activities (1)

Sociedad Española de Inmunología: Sabadell, Catalunya, ES

2004-12-01 to present | Member (Laboratory of Immunology)
Membership
Source: Self-asserted source
Juan Francisco Delgado

Works (11)

7<SUP>th</SUP> European Conference of Immunology 1-4 September, 2024 Dublin, Ireland Abstracts

European Journal of Immunology
2024 | Journal article
Source: check_circle
Web of Science Researcher Profile Sync

Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys® Immunoassay in the S Protein Vaccination Era

Viruses
2023-04-07 | Journal article
Contributors: Juan Francisco Delgado; Mònica Vidal; Germà Julià; Gema Navarro; Rosa María Serrano; Eva van den Eynde; Marta Navarro; Joan Calvet; Jordi Gratacós; Mateu Espasa et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

SARS-CoV-2 Spike Protein Vaccine-Induced Immune Imprinting Reduces Nucleocapsid Protein Antibody Response in SARS-CoV-2 Infection.

Journal of immunology research
2022-07-29 | Journal article
Contributors: Juan Francisco Delgado
Source: Self-asserted source
Juan Francisco Delgado
grade
Preferred source (of 3)‎

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers

Viruses
2022-06 | Journal article | Author
Contributors: Juan Francisco Delgado; Antoni Berenguer-Llergo; Germà Julià; Gema Navarro; Mateu Espasa; Sara Rodríguez; Noemí Sánchez; Eva Van Den Eynde; Marta Navarro; Joan Calvet et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 4)‎

Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study.

Diagnostics (Basel, Switzerland)
2022-03-12 | Journal article
Source: Self-asserted source
Juan Francisco Delgado

Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission.

Scientific reports
2022-01-12 | Journal article
Source: Self-asserted source
Juan Francisco Delgado
grade
Preferred source (of 2)‎

Antibody response after SARS-CoV-2 vaccination in a Healthcare workers cohort

European Journal of Immunology
2021 | Journal article
Contributors: Francisco Delgado, Juan; Navarro, Gema; Espasa, Mateu; Rodriguez, Sara; Julia, Germa; Maria Serrano, Rosa; Sanfeliu, Isabel; Van den Eynde, Eva; Navarro, Marta; Pena, Pilar et al.
Source: check_circle
Web of Science Researcher Profile Sync

Optimal technique for measuring the IgE blocked by omalizumab

European Respiratory Journal
2014 | Journal article
Contributors: Domingo, Christian; Sogo, Ana; Delgado, Juan Francisco; Bosque, Monserrat; Domingo, Xavier; Monserrate, Daniel-Ross; Ollert, Markus; Amengual, Maria Jose
Source: check_circle
Web of Science Researcher Profile Sync

Identification and Molecular Characterization of Two New Mutations Causing C5 Deficiency in Three Un-Related North-African Families

Journal of Clinical Immunology
2014-10 | Journal article
Part of ISSN: 0271-9142
Part of ISSN: 1573-2592
WOSUID:

WOS:000347389100218

Contributors: Colobran, R; Franco-Jarava, C; Martin-Nalda, A; Minguell, L; Baena, N; Delgado, JF; Pujol-Borrell, R; Soler-Palacin, P; Hernandez-Gonzalez, M
Source: Self-asserted source
Juan Francisco Delgado
grade
Preferred source (of 2)‎

Paediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes display small clinical differences.

Acta paediatrica (Oslo, Norway : 1992)
2014-03-17 | Journal article
Source: Self-asserted source
Juan Francisco Delgado
grade
Preferred source (of 2)‎

Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy

Rheumatology
2009-05-29 | Journal article | Author
SOURCE-WORK-ID:

824b3855-1c7b-427e-b9ea-227a1098434a

EID:

2-s2.0-65849204034

Contributors: Moises Labrador-Horrillo; Ma Angeles Martinez; Albert Selva-O'Callaghan; Juan Francisco Delgado; Xavier Martínez-Gómez; Ernesto Trallero-Araguás; Jose Luis Rodriguez-Sanchez; Miguel Vilardell Tarres
Source: check_circle
Universitat Autònoma de Barcelona
grade
Preferred source (of 2)‎

Peer review (22 reviews for 8 publications/grants)

Review activity for Antibodies. (10)
Review activity for Expert opinion on biological therapy (1)
Review activity for Expert review of vaccines (1)
Review activity for International journal of infectious diseases. (3)
Review activity for Journal of clinical laboratory analysis. (1)
Review activity for Journal of personalized medicine. (1)
Review activity for Open forum infectious diseases. (1)
Review activity for Vaccines. (4)